<DOC>
	<DOCNO>NCT02117713</DOCNO>
	<brief_summary>This multicentre , extension study LUM001 child diagnose Alagille Syndrome complete participation core LUM001 treatment protocol . The primary objective evaluate long-term safety tolerability LUM001 . Efficacy assess evaluate effect LUM001 biochemical marker pruritus associate Alagille Syndrome .</brief_summary>
	<brief_title>An Extension Study Evaluate Long-Term Safety Durability Effect LUM001 Treatment Cholestatic Liver Disease Pediatric Subjects With Alagille Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Alagille Syndrome</mesh_term>
	<mesh_term>Cholestasis</mesh_term>
	<criteria>1 . Male female , 12 month 18 year age . 2 . Completed participation LUM001301 protocol . 3 . Females childbearing potential must negative urine pregnancy test Baseline Visit . 4 . Sexually active female must prepare use effective method contraception trial . 5 . Caregivers ( age appropriate subject ) must access phone schedule call study site . 6 . Caregivers ( age appropriate subject ) must willing able complete daily electronic diary . 1 . Experienced adverse event serious adverse event ( SAE ) relate study drug LUM001301 protocol lead discontinuation subject core study . 2 . Any condition abnormality may compromise safety subject , interfere subject participate completing study . 3 . History presence gallstone kidney stone . 4 . History nonadherence subject 's participation LUM001301 protocol . Nonadherence define dose compliance1 le 80 % LUM001301 protocol .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>